Haiyan Wei

No ORCID on file · 1 paper in corpus

nonrandomized-trial 2023

Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study

Advances in therapy ·doi:10.1007/s12325-023-02617-8

INTRODUCTION: Triptorelin is available as 1- and 3-month prolonged-release (PR) formulations; at the time of the study, only the former was approved for central precocious puberty (CPP) in China. This study assessed the efficacy and safety …